Study on the anti fibrotic mechanism of emodin in inhibiting hepatic stellate cell activation by regulating the FGF19/FGFR4 pathway
Objective To investigate the anti fibrotic mechanism of emodin in inhibiting hepatic stellate cell(HSC)activation by regulating the FGF19/FGFR4 pathway.Methods Human HSC cell line LX-2 cells were cultured in vitro and grouped into control group,low-dose emodin group,high-dose emodin group,H3B-6527 group(FGF19/FGFR4 signaling pathway inhibitor),high-dose emodin+oe-NC group and high-dose emodin+oe-FGFR4 group.CCK-8 was ap-plied to detect cell proliferation;flow cytometry was applied to detect cell apoptosis;qRT-PCR experiment was applied to detect the expression of FGF19 and FGFR4 genes in cells.Western blotting was applied to detect the levels of Col-Ⅰ,Col-Ⅲ,α-SMA,Bcl-2,Bax,FGF19 and FGFR4 proteins.Results Compared with the control group,the OD450(24 h,48 h)value,FGF19 mRNA,FGFR4 mRNA expression,Col-Ⅰ,Col-Ⅲ,α-SMA,Bcl-2,FGF19,FGFR4 pro-tein expression in LX-2 cells in low-dose and high-dose emodin groups and H3B-6527 group were obviously reduced,and the apoptosis rate and Bax protein expression were obviously increased(P<0.05).Compared with the high-dose emodin group,there was no statistically obvious difference in various detection indicators of LX-2 cells in the H3B-6527 group(P>0.05).Overexpression of FGFR4 weakened the effects of emodin on the behavior of LX-2 cells and protein expression.Conclusion Emodin can inhibit the biological activity of HSC and achieve anti liver fibrosis effects by in-hibiting the FGF19/FGFR4 pathway.
NETL
NSTL
万方数据
